Gilead Sciences, Inc. $GILD Position Trimmed by Cerity Partners LLC

Cerity Partners LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 245,790 shares of the biopharmaceutical company’s stock after selling 8,230 shares during the quarter. Cerity Partners LLC’s holdings in Gilead Sciences were worth $27,251,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of GILD. Rothschild Investment LLC lifted its holdings in Gilead Sciences by 1.9% in the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares during the last quarter. Archer Investment Corp raised its position in shares of Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. EPG Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 2.0% in the 2nd quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock worth $513,000 after purchasing an additional 89 shares during the last quarter. Southland Equity Partners LLC lifted its holdings in shares of Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after purchasing an additional 92 shares during the last quarter. Finally, Putney Financial Group LLC boosted its position in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Rothschild & Co Redburn increased their price objective on shares of Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Needham & Company LLC lifted their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Argus upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Finally, Wolfe Research raised their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.65.

Gilead Sciences Stock Down 0.0%

GILD stock opened at $121.19 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The company has a market capitalization of $150.36 billion, a price-to-earnings ratio of 18.79, a price-to-earnings-growth ratio of 0.67 and a beta of 0.32. The firm’s 50-day moving average is $121.11 and its two-hundred day moving average is $115.44. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period last year, the firm posted $2.02 earnings per share. The business’s revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the transaction, the chief financial officer directly owned 154,555 shares of the company’s stock, valued at $19,354,922.65. The trade was a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the sale, the insider directly owned 107,193 shares of the company’s stock, valued at $13,491,310.98. The trade was a 20.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 135,757 shares of company stock worth $16,616,127. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.